Verici Dx validated a pre-transplant kidney rejection risk test that aims to estimate early acute rejection risk before transplantation. The company’s Pre-Transplant Risk Assessment (PTRA) measures a 29-gene RNA expression immune signature in a prospective clinical study published in Kidney360, with the goal of stratifying recipients independently of donor characteristics and clinical risk factors. The article contrasted the approach with established and emerging post-transplant strategies, including donor-derived cell-free DNA tests that assess rejection risk after transplant. Verici said the signature is intended to answer where a patient “is” immunologically when preparing for surgery, addressing a gap created by limited predictive value from purely pre-op clinical history. If adopted, pre-transplant risk stratification could change monitoring intensity, immunosuppression selection, and trial design by enabling earlier identification of recipients most likely to benefit from tailored regimens.